Climodien^® (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints

References

• Prelevic GM, Jacobs HS. Menopause and post-menopause. Baillière's Clin Endocrinol Metab 1997;1:311–40
   Google Scholar
• Grady D, Rubin SM, Pettiti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016–37
   PubMed Web of Science ®Google Scholar
• Martin KA, Freeman MF. Postmenopausal hormonal replacement therapy. N Engl J Med 1993;328:1115–17
   PubMed Web of Science ®Google Scholar
• Belchetz PE. Hormone treatment of postmeno-pausal women. N Engl J Med 1994;330:1062–71
   PubMed Web of Science ®Google Scholar
• te Velde ER, van Leusden HAIM. Hormonal treatment for the climacteric: alleviation of symp-toms and prevention of postmenopausal disease. Lancet 1994;343:654–8
   PubMed Web of Science ®Google Scholar
• Bittner V. Estrogens, lipids and cardiovascular disease: no easy answer. J Am Coll Cardiol 2001;37:431–3
   PubMed Web of Science ®Google Scholar
• Eriksen EF, Kassem M, Langdahl B. European and North American experience with HRT for the prevention of osteoporosis. Bone 1996; 19:S179–83
   Google Scholar
• Beresford SAA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458–61
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replace-ment with and without progestins. J Natl Cancer Inst 1999;91:1131–7
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Ulrich LG, Barlow DH, et al. The endometrial response to sequential and continu-ous combined oestrogen—progestogen replace-ment therapy. Br J Obstet Gynaecol 2000;107: 1392–400
   Google Scholar
• The Writing Group for the PEP trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Post-menopausal Estrogen/Progestin Interventions (PEP!) Trial. J Am Med Assoc 1996;275:370–5
   Google Scholar
• Oosterbaan HP, van Buuren AHJAM, Schram JHN, et al. The effects of continuous combined transdermal oestrogen—progestogen treatment on bleeding patterns and the endometrium in postmenopausal women. Maturitas 1995;21: 211–19
   PubMed Web of Science ®Google Scholar
• Gräser T, Muller A, Mellinger U, Muck AO, Lippert TH, Oettel M. Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest — a dose-ranging study. Maturitas 2000;35:253–1
   Google Scholar
• Gräser T, Koytchev R, Mailer A, Oettel M. Com-parison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest® for continuous combined hormone replacement therapy in postmenopausal women. Climacteric 2000;3:109–18
   Google Scholar
• Stanczyk FZ. Introduction: structure—function relationships, metabolism, pharmacokinetics and potency of progestins. Drugs Today 1996;32 (Suppl H):1–14
   Google Scholar
• Gräser T, Oettel M. Organ targeting with the oral progestin dienogest. Drugs Today 1996;32 (Suppl H):43–55
   Google Scholar
• Katsuki Y, Shibutani Y, Aoki D, Nozawa S. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer 1997;79:169–76
   PubMed Web of Science ®Google Scholar
• Karch FE, Lasagna L. Adverse drug reactions. A critical review. J Am Med Assoc 1975;234: 1236–41
   PubMed Web of Science ®Google Scholar
• Kupperman HS, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenor-rheal indices. J ain Endocrinol 1953;13: 688–703
   PubMed Web of Science ®Google Scholar
• Marslew U, Riis B, Christiansen C. Progestogens: therapeutic and adverse effects in early post-menopausal women. Maturitas 1991;13:7–16
   Google Scholar
• Obel EB, Munk-Jensen N, Svenstrup B, et al. A two-year double-blind controlled study of the clinical effect of combined and sequential post-menopausal replacement therapy and steroid metabolism during treatment. Maturitas 1993; 16:13–21
   PubMed Web of Science ®Google Scholar
• Weinstein L, Bewtra C, Gallagher JC. Evaluation of a continuous combined low-dose regimen of estrogen—progestin for treatment of the meno-pausal patient. Am J Obstet Gynecol 1990;162: 1534–42
   Google Scholar
• Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gyneco/ 1995;86:306–16
   Google Scholar
• Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results: the relationship or reduction inincidence of coronary heart disease to choles-terol. J Am Med Assoc 1984;251:365–74
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Manson ME, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:435–61
   Google Scholar
• Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the com-bined use of estrogens and progestins in post-menopausal women. Arch Intern Med 1994;154: 1333–9
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280:605–13
   Google Scholar
• The European Agency for the Evaluation of Medicinal Products: Human Medicines Evalua-tion Unit: Committee for Proprietary Medicinal Products (CPMP). Points to consider on hormone replacement therapy. London, November 1997
   Google Scholar
• Christiansen C, Riis BJ. Five years with continu-ous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern. Br J Obstet Gynaecol 1990; 97:1087–92
   PubMedGoogle Scholar